Drug Profile
Research programme: PAR-2 antagonists - EntreMed
Alternative Names: 520p; p520Latest Information Update: 19 Dec 2008
Price :
$50
*
At a glance
- Originator EntreMed
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 19 Dec 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 21 Jul 2006 This programme is still in active development